[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]
Views 7,621
Citations 0
Editorial
April 2017

JAMA Oncology—The Year in Review, 2016

Author Affiliations
  • 1Editor, JAMA Oncology
  • 2University of Washington and Fred Hutchinson Cancer Research Center, Seattle
 

Copyright 2017 American Medical Association. All Rights Reserved.

JAMA Oncol. 2017;3(4):450-451. doi:10.1001/jamaoncol.2016.7045

Having completed JAMA Oncology’s second full year of publication, we are incredibly proud of how the journal has flourished over the past year. We would like to thank our authors, reviewers, and readers for the substantial contributions made to the journal in 2016. The editorial board and I are honored to have the opportunity to serve the oncology community by offering original, innovative, and timely scientific content that has a direct impact on researchers, clinicians, and the patients we serve.

First and foremost, I would like to thank our authors. In 2016, we published 403 total manuscripts including 104 research articles, 48 Viewpoints, 1 Special Communication, and 77 Editorials and Invited Commentaries. The 17 Review articles published this year covered topics ranging from the use of genomics for cancer immune therapy to recommendations for surveillance mammography in older patients with breast cancer. The quality of our published articles is reflected in the 1.1 million visits to our website to access content and more than 11 439 media mentions of JAMA Oncology articles in print, online, and news services this past year.

We received a total of 1767 manuscript submissions in 2016—an impressive 16% increase in submissions from the year prior. These submissions to JAMA Oncology included 1064 Original Investigations, of which 87 were clinical trial reports, 85 were meta-analyses, and 66 were reviews.

In 2016, the overall acceptance rate was 21%. Our acceptance rate for Original Investigations was 9%, 24% for clinical trials, and 9% for meta-analyses. We accepted 35% of review manuscripts, 22% of submitted Research Letters, 45% of Viewpoints, and 63% of Clinical Challenges. JAMA Oncology is indexed in PubMed and Thomson Reuters’ Science Citation Index, and we expect our first Impact Factor designation in June of this year. Articles that received the most citations and news and social media attention are listed in the Table.1-5 More detailed statistics are also listed in the Table.

Table.  
JAMA Oncology Statistics for 2016
JAMA Oncology Statistics for 2016

We are also very grateful to our global consortium of peer reviewers who contributed to the journal this year. We are pleased to acknowledge their contribution to JAMA Oncology by publishing online the names of the more than 900 experts who completed a manuscript review in 2016.6 This group of renowned laboratory, clinical, quantitative, and statistical scientists provided comprehensive reviews of the submitted manuscripts in an average of just 14 days. Their timely and high-quality work for the journal has allowed JAMA Oncology to maintain a median time from receipt of a manuscript to acceptance, including time for author revision, in an impressive 41 days. The ability to rapidly review and return a decision on our submissions within 3 weeks of submission ensures that authors receive a detailed and efficient service in reviewing their work, and that those important findings are available to the oncology community as quickly as possible. We would not be able to provide this service without our expert peer reviewers and their commitment to providing prompt and high-quality reviews for the journal.

Finally, we would like to thank our readers. We provide our Table of Contents of newly published material each week by email to 24 357 readers. This past year, more than 1.7 million copies of published JAMA Oncology articles were downloaded. We thank you for your feedback.

We likewise launched a variety of new features this year—from a series of Viewpoints on annual meeting highlights to a newly responsive and streamlined web design for our online content—and we are proud to continue offering the most innovative, provocative, and timely research for scientists, clinicians, and trainees in the field of oncology worldwide. We encourage our readers to stay involved with the journal by submitting Letters to the Editor and offering recommendations for new topics that you would like to see covered in future issues. Your suggestions make this interdisciplinary oncology journal dynamic and current—keep them coming!

We have truly enjoyed being involved in JAMA Oncology’s continued success this year and we look forward to the year ahead. We could not have done it without you. We invite all of our readers to sign up for email Table of Contents at http://www.jamaoncology.com, to follow us on Twitter @JAMAOnc, or to friend us on Facebook. We will keep you up to date on the most important discoveries influencing cancer care.

Back to top
Article Information

Corresponding Author: Mary L. (Nora) Disis, MD, University of Washington and Fred Hutchinson Cancer Research Center, 850 Republican St, Brotman 221, PO Box 358050, Seattle, WA 98195-8050 (ndisis@uw.edu).

Published Online: February 9, 2017. doi:10.1001/jamaoncol.2016.7045

Conflict of Interest Disclosures: None reported.

References
1.
Song  M, Giovannucci  E.  Preventable incidence and mortality of carcinoma associated with lifestyle factors among white adults in the United States.  JAMA Oncol. 2016;2(9):1154-1161. doi:10.1001/jamaoncol.2016.0843PubMedGoogle ScholarCrossref
2.
Global Burden of Disease Cancer Collaboration.  Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the Global Burden of Disease study  [published online December 3, 2016].  JAMA Oncol. doi:10.1001/jamaoncol.2016.5688Google Scholar
3.
Nikiforov  YE, Seethala  RR, Tallini  G,  et al.  Nomenclature revision for encapsulated follicular variant of papillary thyroid carcinoma: a paradigm shift to reduce overtreatment of indolent tumors.  JAMA Oncol. 2016;2(8):1023-1029. doi:10.1001/jamaoncol.2016.0386PubMedGoogle ScholarCrossref
4.
Antonarakis  ES, Lu  C, Luber  B,  et al.  Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer.  JAMA Oncol. 2015;1(5):582-591.PubMedGoogle ScholarCrossref
5.
Narod  SA, Iqbal  J, Giannakeas  V, Sopik  V, Sun  P.  Breast cancer mortality after a diagnosis of ductal carcinoma in situ.  JAMA Oncol. 2015;1(7):888-896.PubMedGoogle ScholarCrossref
6.
 JAMA Oncology peer reviewers in 2016  [published online February 9, 2017].  JAMA Oncol. doi:10.1001/jamadermatol.2017.0043Google Scholar
×